Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Skin Neoplasms 1Neoplasms, Squamous Cell 1Neoplasms, Basal Cell 1Melanoma 1Carcinoma, Squamous Cell 1Carcinoma, Basal Cell 1

Interventions

pembrolizumab 25Cisplatin 20Carboplatin 14Paclitaxel 11Radiotherapy 9Radiotherapy, Intensity-Modulated 8Docetaxel 8Cetuximab 8Nivolumab 6cemiplimab 5Radiation 5durvalumab 4atezolizumab 3Taxes 3Surveys and Questionnaires 3Fluorouracil 3Drug Therapy 3Cyclophosphamide 3Blood Specimen Collection 3toripalimab 2olaparib 2fludarabine 2avelumab 2alpha-2'-deoxythioguanosine 2aldesleukin 2Surgical Procedures, Operative 2Standard of Care 2Pemetrexed 2Magnetic Resonance Spectroscopy 2vistusertib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Squamous Cell × Risk Factors × 1 year × Clear all
NCT03509467 2025-12-19

Using MC1R Genotype to Impact Melanoma Risk Behavior

H. Lee Moffitt Cancer Center and Research Institute

Phase NA Completed
2,054 enrolled 92 charts
Dermatologic

Carcinoma, Basal Cell, Carcinoma, Squamous Cell, Melanoma, Skin Neoplasms, Neoplasms, Basal Cell, Neoplasms, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡